- The second decade of anti|TNF|a therapy in clinical practice🔍
- A Novel Method for Improving Clinical Response to Anti|TNF ...🔍
- 20 years of experience with tumour necrosis factor inhibitors🔍
- The First Decade of Biologic TNF Antagonists in Clinical Practice ...🔍
- Association Between Tumor Necrosis Factor Inhibitor Exposure and ...🔍
- Managing inadequate response to initial anti|TNF therapy in ...🔍
- Secondary failure of TNF|α inhibitors in clinical practice🔍
- Rituximab versus an alternative TNF inhibitor in patients with ...🔍
The second decade of anti|TNF|a therapy in clinical practice
The second decade of anti-TNF-a therapy in clinical practice - PubMed
Since the late 1990s, tumor necrosis factor alpha (TNF-α) inhibitors (anti-TNFs) have revolutionized the therapy of immune-mediated ...
The second decade of anti-TNF-a therapy in clinical practice
Recent experimental studies have shown that anti-TNFs exert their beneficial effects not only by restoring aberrant TNF-mediated immune ...
The second decade of anti-TNF-a therapy in clinical practice: new ...
Since the late 1990s, tumor necrosis factor alpha (TNF-α) inhibitors (anti-TNFs) have revolutionized the therapy of immune-mediated inflammatory …
The second decade of anti-TNF-a therapy in clinical practice - OUCI
The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era.
The second decade of anti-TNF-a therapy in clinical practice - NET
The second decade of anti‑TNF‑a therapy in clinical practice: new lessons and future directions in the COVID‑19 era. Gerasimos Evangelatos1,2.
The second decade of anti-TNF-a therapy in clinical practice - Altmetric
The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era · Rheumatology International, ...
The second decade of anti-TNF-a therapy in clinical practice: new ...
The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. Evangelatos, Gerasimos; Bamias, Giorgos ...
A Novel Method for Improving Clinical Response to Anti-TNF ...
Primary lack of response and secondary loss of response (LOR) are major obstacles to the use of anti–tumor necrosis factor (TNF)-based therapies in patients ...
20 years of experience with tumour necrosis factor inhibitors
TNF inhibitors are biologic DMARDs approved for the treatment of active RA in mid-1990s. They still represent a valuable therapeutic option.
The First Decade of Biologic TNF Antagonists in Clinical Practice ...
Multiple randomized trials have shown that TNF antagonists are effective for the treatment of patients with either moderate to severe psoriasis or psoriatic ...
Association Between Tumor Necrosis Factor Inhibitor Exposure and ...
Little is known about the inflammatory nondemyelinating CNS events that occur during TNF inhibitor therapy. Case reports have suggested a ...
Managing inadequate response to initial anti-TNF therapy in ...
Anti-tumour necrosis factors (anti-TNFs) are established as first-line biological therapy for rheumatoid arthritis (RA) with over two decades of accumulated ...
Secondary failure of TNF-α inhibitors in clinical practice - OUCI
Acosta-Felquer, An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: Place in therapy, Open Access Rheumatology, № 30, ...
Rituximab versus an alternative TNF inhibitor in patients with ...
Patients were followed for 12 months from the start of the second biological therapy. Assessments included demographic and clinical variables at the time of ...
Clinical application and evaluation of anti-TNF-alpha agents for the ...
By comparing the efficacy, safety and use principle of different treatment options, this review focuses on providing important information about ...
Tumor Necrosis Factor (TNF) Inhibitors
The TNF inhibitors approved by the FDA are infliximab, adalimumab, etanercept, golimumab, and certrolizumab. These agents can be used by themselves or in ...
the development of anti-TNF therapy of rheumatoid arthritis - Elsevier
drugs (DMARDs), translate into convincing evidence for anti-TNF therapy in such patients. The introduction of infliximab into clinical practice has proved its ...
Long-term clinical and real-world experience with Crohn's disease ...
Although anti-tumor necrosis factor (TNF)-α agents are important therapeutic drugs for inflammatory bowel diseases, the incidence of secondary loss of response ...
Secondary failure of TNF-α inhibitors in clinical practice | Request PDF
Antibodies against monoclonal antibodies (adalimumab, infliximab) have been associated with diminished clinical response, while against etanercept are non‐ ...
Failure of anti-TNF treatment in patients with rheumatoid arthritis
In patients who do not achieve LDA or remission, it is necessary to use bDMARDs and then, if the clinical results are insufficient, switch to another biological ...